Q702
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Q702, covering 2025-10-10 to 2026-02-24. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]